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Neutrophils in cystic ﬁbrosis (CF) fail to eradicate pathogens causing lung in-
fections. Studies indicating innate differences in neutrophil activity in CF have
illustrated increased release of proteases from primary granules. Little is known
about degranulation of secondary granules which is mediated by Rab27a. The novel
drug ivacaftor, a CFTR potentiator, restores the function of the G551D mutant CFTR
protein and trials have shown promising clinical results. The aim of this study was
to evaluate abnormalities in CF circulating neutrophils and to investigate the in vivo
ability of ivacaftor to correct dysregulated neutrophil activity in patients with CF.
Puriﬁed neutrophils were exposed to TNFa (10 ng/2×107cells) for 0, 5, 10 or
20min. Degranulation was investigated by Western blot analysis, ELISA and ﬂow
cytometry. Rab27a activation was determined by quantifying bound GTP by coupled
enzymatic reaction.
CF neutrophils released 50% and 75% less secondary and tertiary granules,
respectively (p< 0.05). Upregulation of CD66b, a marker of secondary and tertiary
granule release, to the cell surface was decreased by 40% on CF cells (p< 0.05). In
addition, Rab27a activation was delayed and decreased in CF neutrophils (p< 0.05).
After one year treatment with ivacaftor, degranulation of cells from patients carrying
the G551D mutation increased by 130% to the level of healthy controls (p< 0.05).
In conclusion, altered Rab27a activation causes decreased degranulation of sec-
ondary and tertiary granules in CF neutrophils, an effect corrected by ivacaftor
treatment in those with the G551D mutation, thereby potentially improving neu-
trophil function and bacterial clearance in CF.
